2. Metabolic Enzyme/Protease
  3. Liposome
  4. DMG-pSar25

DMG-pSar25 is a double lipid-tailed polysarcosine lipid with 25 sarcosine moieties, serving as a PEG lipid substitute in lipid nanoparticle formulations for mRNA delivery. DMG-pSar25 supports mRNA delivery in lipid nanoparticle formulations.

For research use only. We do not sell to patients.

DMG-pSar25

DMG-pSar25 Chemical Structure

CAS No. : 2936622-30-7

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
25 mg Get quote
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

DMG-pSar25 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DMG-pSar25 is a double lipid-tailed polysarcosine lipid with 25 sarcosine moieties, serving as a PEG lipid substitute in lipid nanoparticle formulations for mRNA delivery. DMG-pSar25 supports mRNA delivery in lipid nanoparticle formulations[1].

In Vitro

DMG-pSar25 (50 ng firefly luciferase mRNA per well; 18 h) enhances mRNA delivery efficiency in ALC-0315 (HY-138300)-based LNPs in C2C12 and Hep3B cells compared to ALC-0159 PEG controls, while maintaining comparable cell viability[1].
DMG-pSar25 (50 ng firefly luciferase mRNA per well; 18 h) maintains mRNA delivery efficiency in SM-102 (HY-134541)-based LNPs in C2C12 and Hep3B cells compared to DMG-PEG2000 controls, while maintaining comparable cell viability[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DMG-pSar25 Related Antibodies
In Vivo

DMG-pSar25 (0.06 µg mRNA; i.m.; single administration) replacing PEG lipids in ALC-0315 (HY-138170)-based LNPs enhances mRNA delivery efficiency (greater than 5-fold higher total flux) in healthy mice, while SM-102-based LNPs with DMG-pSar25 maintain comparable delivery efficiency to PEG-formulated LNPs, with similar immunogenicity profiles and no induction of anti-PEG antibodies[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice[1]
Dosage: 0.06 µg mRNA
Administration: i.m.; single administration
Result: Produced greater than 5-fold higher total flux (luminescence intensity) than ALC-0315-based LNPs formulated with ALC-0159 PEG lipid.
Resulted in significantly higher hEPO levels in muscle (P = 0.008) compared to ALC-0315-based LNPs with ALC-0159 PEG lipid; hEPO levels in blood were similar between the two groups.
Showed comparable total flux and hEPO levels (blood and muscle) to SM-102-based LNPs formulated with DMG-PEG2000.
Exhibited cytokine/chemokine profiles largely similar to PEG-formulated LNPs, with SM-102-based DMG-pSar25 LNPs showing significantly higher levels of G-CSF (P = 0.005), IL-6 (P = 0.0003), CXCL10 (P = 0.04), CXCL1 (P = 0.0008), M-CSF (P = 0.01), CXCL9 (P = 0.04), and CCL4 (P = 0.02) compared to SM-102-based DMG-PEG2000 LNPs; ALC-0315-based DMG-pSar25 LNPs showing significantly higher levels of IFNγ (P = 0.02), IL-6 (P = 0.008), IL-4 (P = 0.04), and IL-5 (P = 0.02), and significantly lower IL-2 (P = 0.04) compared to ALC-0315-based ALC-0159 LNPs.
Did not induce anti-PEG IgG production upon repeat administration, whereas repeat administration of PEG-formulated LNPs did (P = 0.04).
Did not cause significant elevation of plasma aspartate transaminase (AST) and alanine transaminase (ALT) levels compared to PBS-treated mice.
Molecular Weight

2416.93

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CN(C(CCC(OC[C@]([H])(OC(CCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCC)=O)=O)=O)C(CNCC)=O.[n]
Structure Classification
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

Ethanol : ≥ 50 mg/mL (20.69 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.4137 mL 2.0687 mL 4.1375 mL
5 mM 0.0827 mL 0.4137 mL 0.8275 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.0%

SDS (252 KB)

COA (242 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
Ethanol 1 mM 0.4137 mL 2.0687 mL 4.1375 mL 10.3437 mL
5 mM 0.0827 mL 0.4137 mL 0.8275 mL 2.0687 mL
10 mM 0.0414 mL 0.2069 mL 0.4137 mL 1.0344 mL
15 mM 0.0276 mL 0.1379 mL 0.2758 mL 0.6896 mL
20 mM 0.0207 mL 0.1034 mL 0.2069 mL 0.5172 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DMG-pSar25 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DMG-pSar252936622-30-7Liposomepolysarcosine lipidlipid nanoparticle formulationsSM-102firefly luciferase mRNAanti-PEG antibodiesmRNA deliveryHep3B cellsALC-0315C2C12 cellshealthy miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DMG-pSar25
Cat. No.:
HY-N16040
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.